Drug Trial Radar · NCT04806464
Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
44
Planned (sponsor's estimate)
Start
Mar 16, 2021
Primary completion
Mar 21, 2022
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to determine the safety and tolerability of VG161 and find recommended dose of VG161. Part 2: This part is extended dose design to determine the effectiveness of VG161.
Conditions
- Primary Liver Cancer
Interventions
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))Drug
Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part1: MTD/Recommended doseTime frame: 7 month
- Part1: Occurence of DLTTime frame: 1month
- Part1: Numbers of DLTTime frame: 1 month
- Part1: Occurence of AE and SAE(NCI CTCAE 5.0)Time frame: 7 months
- Part1: Frequency of AE and SAE(NCI CTCAE 5.0)Time frame: 7 months
- Part2:ORRTime frame: 7 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.